Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $71 | $59 | $71 | $137 |
| Short-Term Investments | $194 | $216 | $222 | $176 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $4 | $4 | $4 |
| Total Curr. Assets | $271 | $279 | $296 | $316 |
| Property Plant & Equip (Net) | $16 | $17 | $18 | $18 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $17 | $18 | $19 | $20 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $288 | $297 | $315 | $336 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $3 | $1 |
| Short-Term Debt | $3 | $3 | $3 | $3 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $10 | $10 | $8 | $11 |
| Total Curr. Liab. | $15 | $15 | $14 | $15 |
| LT Debt | $7 | $8 | $9 | $9 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $1 | $1 | $1 |
| Total NC Liab. | $8 | $9 | $9 | $10 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22 | $24 | $24 | $25 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$328 | -$307 | -$285 | -$262 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $593 | $580 | $577 | $573 |
| Total Equity | $266 | $273 | $292 | $310 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $288 | $297 | $315 | $336 |
| Net Debt | -$61 | -$48 | -$59 | -$124 |